Cell-surface galactose-containing N-linked glycans (Gal-N-glycans)

Cell-surface galactose-containing N-linked glycans are complex oligosaccharides covalently attached to asparagine residues of membrane-bound proteins, forming a critical part of the cellular glycocalyx (Varki et al., 2017). These glycans often terminate in galactose or N-acetyllactosamine (LacNAc) units, which serve as essential recognition motifs for endogenous lectins, such as galectins and the asialoglycoprotein receptor (ASGPR) (D'Alessio et al., 2020). Biologically, they are involved in protein folding, cell-cell adhesion, and the regulation of glycoprotein half-life in circulation (Essentials of Glycobiology, 3rd Ed). In disease states, particularly oncology, aberrant galactosylation patterns are associated with tumor progression, metastasis, and the creation of an immunosuppressive microenvironment through interactions with Galectin-3 (Zhou et al., 2021). Therapeutic strategies leverage these glycans as docking sites for liver-specific drug delivery using galactose or GalNAc conjugates, as seen in RNAi therapeutics like Inclisiran (Springer & Dowdy, 2018). Additionally, small molecule and polysaccharide inhibitors (e.g., Belapectin) are being developed to block the interaction between these glycans and galectins to treat fibrosis and cancer (DrugBank, 2024).

Other names

Galactose-terminated N-glycansGalactosylated N-linked oligosaccharidesTerminal galactose glycansAsialoglycansGalactose-containing N-glycans

Targeting involves the use of galactose or N-acetylgalactosamine (GalNAc) clusters to trigger receptor-mediated endocytosis via the asialoglycoprotein receptor (ASGPR) for intracellular drug delivery, or the use of inhibitors to block the interaction between terminal galactose residues and galectins to modulate immune and fibrotic pathways (Springer & Dowdy, 2018; Zhou et al., 2021).